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Objectives. This study compared the effects of amlodipine, 
atenolol and their combination on ischemia during treadmill 
testing and 48-h ambulatory monitoring. 
Background. It is not known whether anti-ischemic drugs exert 
similar effects on ischemia during ambulatory monitoring and 
exercise treadmill testing. 
Methods. Patients with stable coronary artery disease and 
ischemia during treadmill testing and ambulatory monitoring 
were randomized to receive amiodipine (n = 51) or atenolol (n = 
49). Each group underwent a counterbalanced, crossover evalua- 
tion of single drug and placebo, followed by evaluation of the 
combination. 
Results. Amlodipine and the combination prolonged exercise 
time to 0.1.mV ST segment depression by 29% and 34%, respec- 
tively (p < 0.001) versus 3% for atenoloi (p = NS). During 
ambulatory monitoring, the frequency of ischemic episodes de- 
creased by 28% with amlodipine (p = 0.083 INS]), by 57% with 
atenolol (p < 0.001) and by 72% with the combination (p < 0.05 
vs. both single drugs; p < 0.001 vs. placebo). Suppression of 
ischemia during exercise testing and ambulatory monitoring was 
similar in patients with and without exercise-induced angina. 
Exercise time to angina improved by 29% with amlodipine (p < 
0.01), by 16% with atenolol (p < 0.05) and by 39% with the 
combination (p < 0.005 vs. placebo, atenolol and amlodipine). In 
patients with angina, total exercise time improved by 16% with 
amlodipine (p < 0.001), by 4% with atenolol (p = NS) and by 19% 
with the combination (p < 0.05 vs. placebo and either single 
drug). In those patients without angina, no therapy significantly 
improved total exercise time. 
Conclusions. Ischemia during treadmill testing was more effec- 
tively suppressed by amlodipine, whereas ischemia during ambu- 
latory monitoring was more effectively suppressed by atenolol. The 
combination was more effective than either single drug in both 
settings. 
(J Am Coil Cardiol 1995;25:619-25) 
Among patients with positive treadmill tests, ischemia during 
ambulatory electrocardiographic (ECG) monitoring confers an 
additional, independent risk of subsequent cardiovascular 
events (1,2). Considerable r search as focused on pathophys- 
iologic differences between ischemia during ambulatory mon- 
itoring and exercise treadmill testing (3-7). One aspect of this 
is whether ischemia in these two settings responds to anti- 
ischemic drugs in the same manner. During treadmill testing, 
both beta-adrenergic blocking agents and calcium antagonists 
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have been shown to delay the onset of ischemia and improve 
exercise times in patients with angina. Many studies (8-13) 
show that beta-blockers educe the extent of ischemia during 
ambulatory monitoring. Results for the dihydropyridine cal- 
cium antagonists have been less consistent. A recent multi- 
center study (9) found the immediate-release pr paration of 
nifedipine to be relatively ineffective in suppressing ischemia 
during ambulatory monitoring, but other studies (14,15) found 
long-acting nifedipine preparations to be effective in this 
regard. Other data (11,16-20) suggest that the combination of
a dihydropyridine with a beta-blocker is particularly effica- 
cious. 
Amlodipine is a "third-generation" calcium antagonist with 
a gradual onset of action and prolonged half-life (21) that 
causes little or no reflex tachycardia (22). These properties 
may improve its efficacy in suppressing ischemia, both alone 
and in combination with a beta-blocker (18,23,24). The Cana- 
dian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) 
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was therefore designed to compare the anti-ischemic effects of 
amlodipine, atenolol and their combination during treadmill 
testing and ambulatory monitoring. 
Methods  
Patients. Screening. The study was conducted in the nine 
Canadian centers listed in the Appendix. Patients with docu- 
mented coronary artery disease and previous positive treadmill 
test results were screened. Criteria for documented coronary 
artery disease were 1) at least one coronary artery stenosis 
>70% lumen diameter eduction on coronary angiography; 
2) a documented previous myocardial infarction; or 3) a 
previous radionuclide test reported as showing a reversible 
peffusion defect. The criterion for a positive treadmill test 
result was ->0.1 mV flat or downsloping ST segment depression 
measured 0.08 s after the J point. 
Screening procedure. The study was approved by the re- 
search ethics boards of the participating institutions. Potential 
candidates were identified by direct referral from physicians 
practicing in participating institutions. All patients creened 
provided written informed consent. Patients received two 
tablets every morning resembling amlodipine (10 rag) and 
atenolol (100 mg). Beta-blockers were tapered and withheld 
for at least 1 week, and other anti-ischemic medications were 
stopped for at least 5 half-lives of the individual drug. Patients 
then underwent treadmill testing using the Bruce protocol and 
48-h ambulatory monitoring. 
Eligibility criteria. To be eligible, the patient had to have 
positive findings on the screening treadmill test according to 
the previous criterion. The presence of angina during treadmill 
testing was not a criterion for eligibility. In addition, the 48-h 
ambulatory ecording had to include three or more episodes of 
continuous ST segment depression of at least 0.1 mV lasting 
for at least 1 rain or at least 10 min of total ST segment 
depression if there were only one or two episodes. These 
criteria were based on a pilot study that showed that the two 
each excluded approximately the same number of patients. 
Exclusion criteria. Excluded were those patients with unsta- 
ble symptoms within the previous 3 months, cardiac surgery or 
stroke within the previous 6 months, congestive heart failure, 
hemodynamically significant valvular disease, sinus bradycar- 
dia <60 beats/rain on a 12-lead ECG or any ECG abnormality 
that would preclude interpretation of the ST segment on 
ambulatory monitoring. The latter included atrial fibrillation, 
frequent atrial or ventricular premature beats, Q waves in both 
inferior and lateral eads, Wolfe-Parkinson-White syndrome, 
left or right bundle branch block without an interpretable ST 
segment or rest ST segment elevation or depression of 0.1 mV 
in the inferior and lateral eads. 
Randomization and study design. Patients were randomized 
to a crossover, single-drug evaluation of amlodipine versus 
placebo (n = 51) or atenolol versus placebo (n = 49) (Fig. 1). 
Each group underwent a counterbalanced crossover evaluation 
of placebo and active single drug. Patients in both groups were 
then evaluated with a combination ofamlodipine plus atenolol. 
Screening (N=194) I 
_ _  RANDOMIZATION (N=I00) I 
[ Am|°aipine(N=Sl) I k Atenolol(N=49) ] 
-U- -U- -U- -U- 
1 VT o-1 
-U- ~ -U- 
COMBINATION ] 
Figure 1. CASIS design. PBO = placebo. 
Throughout the study, patients received two tablets every 
morning: amlodipine (5 to 10 rag), or its matching placebo, and 
atenolol (50 to 100 mg), or its matching placebo. 
Dose titration. Single-drug evaluation. Amlodipine was ini- 
tiated at a dose of 5 mg daily and atenolol at 50 mg daily. After 
1 week this was increased to 10 mg of amlodipine and 100 mg 
of atenolol, unless the patient experienced side effects, unac- 
ceptable hypotension (symptomatic or decrease >10% of 
systolic pressure) or bradycardia (<60 beats/min on a rest 
ECG). If the higher dose was not tolerated, patients were 
back-titrated tothe lower dose. Patients unable to tolerate the 
lower dose were dropped from the efficacy evaluation but were 
included in the safety evaluation. Patients received the final 
titrated dosage for at least 2 weeks before evaluation with 
treadmill testing and ambulatory monitoring. 
Combination therapy. Combination therapy was initiated at 
the final dose of active single drug plus the low dose of the 
alternative agent. If this was well tolerated, the alternative 
agent was increased after 1 week. If side effects occurred, the 
alternative agent was back-titrated. Patients received the final 
titrated dosage of combination therapy for at least 2 weeks 
before being evaluated with treadmill testing and ambulatory 
monitoring. 
Blinding and compliance. Evaluations of placebo and 
single-drug therapy were evaluated in double-blinded manner 
in that the patient and the investigator were unaware of 
treatment assignment. Combination therapy was evaluated in
single-blinded manner in that investigator knew the treatment 
assignment. Personnel interpreting exercise treadmill tests and 
ambulatory monitoring remained unaware of treatment assign- 
ment until the end of the study. Medications were supplied to 
clinical centers in prearranged kits covering all possible con- 
tingencies. Compliance was evaluated by pill counts. 
Evaluation of e~eacy. Exercise treadmill testing. Treadmill 
testing using the Bruce protocol was performed uring screen- 
ing and during each treatment evaluation (placebo, single 
drug, combination). Tests were performed within 1 h of the 
same time of day for each patient, at least 2 h after the patient 
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took the study medications. The 12-lead ECG was monitored 
continuously. ST segment depression was measured at 0.08 s 
after the J point in the ECG lead showing maximal ST segment 
depression during the baseline test. Blood pressure and heart 
rate were recorded at baseline, at the end of each exercise 
stage, at the time of 0.1-mV ST segment depression, at peak ST 
segment depression and at peak exercise. The principal inves- 
tigator at each clinical center interpreted the exercise tests. 
The method of interpretation was supervised by the coordinat- 
ing center (University of Ottawa Heart Institute) to ensure 
consistency across centers. 
Ambulatory monitoring. Ambulatory monitoring was per- 
formed during screening and placebo, single-drug and combi- 
nation treatment. Two consecutive 24-h recordings were per- 
formed using a Marquette model 8500 (Marquette Electronics 
Inc.) or Del Mar Avionics model 459 three-channel r corder. 
Bipolar electrodes were attached to record leads Vs, V 2 and 
aVF. All tapes were calibrated. Patients were instructed to 
maintain their normal daily routine and to record activities, 
symptoms and medications in a diary. 
Ambulatory ECG analysis. Ambulatory monitoring record- 
ings were analyzed centrally at the Ottawa Heart Institute 
using a Marquette 8000XP scanner (Marquette Electronics 
Inc.). Personnel involved in this analysis were unaware of 
patient identity and treatment assignment. Ischemic episodes 
were validated by visual inspection of hard copy ECG tracings 
printed at 25 mm/s. The definition of an ischemic episode was 
->0.1 mV of flat or downsloping ST segment depression or 
0.15 mV of slowly upsloping ST segment depression, lasting at 
least 1 min. An isoelectric segment of at least 1 min was 
required between episodes. The duration of ischemia was 
calculated from onset to offset of 0.1 mV of ST segment 
depression. 
Statistical analysis. Data were analyzed at the Ottawa 
Heart Institute using Systat for DOS and Windows (Systat 
Inc.), version 5.02. Baseline characteristics were compared 
using the chi square or Fisher exact est for categoric data and 
the Student statistic for continuous data. The crossover 
design allowed intrasubject comparisons among each single 
drug therapy, placebo and combination therapy, thereby in- 
creasing the statistical power of these comparisons. To control 
for carryover effects, order of treatment was entered as a factor 
into repeated measures analysis of variance models. A two- 
tailed significance l vel of 5% was used, with the Bonferroni 
correction applied for multiple related comparisons. The dis- 
tributions of episode frequency, total ischemia duration and ST 
segment time integral on ambulatory monitoring were skewed. 
To adjust for this, parametric statistical tests were performed 
on square root-transformed data, and ischemia suppression 
was determined using the adjusted means calculated as (mean 
of square root-transformed data) 2. Treadmill testing data were 
normally distributed and were not transformed. 
Time to angina was analyzed as a secondary end point for 
the subset of patients reporting angina during treadmill testing 
during either placebo or active single-drug therapy. To avoid 
biasing the result in favor of the less effective treatment, total 
Table 1. Clinical and Demographic Features of Randomized 
Study Patients 
Amlodipine Group Atenolol Group 
(n = 51) (n = 49) 
Age (yr) 60.8 (8.0) 60.9 (8.1) 
Male gender 43 (84) 39 (80) 
Female gender 8 (16) 10 (20) 
Histo~ of angina 36 (71) 31 (65) 
Diabetes 8 (16) 2 (4) 
Hypertension 17 (33) 17 (35) 
Smoker 9 (18) 12 (25) 
Previous MI 11 (22) 18 (37) 
Hyperlipidemia 35 (70) 39 (81) 
Data presented are mean value (SD) or number (%) of patients. MI = 
myocardial infarction. 
exercise time was substituted for time to angina if angina did 
not occur during the other treatments. This assumes that 
angina would have occurred at peak exercise had the patient 
not stopped for other reasons and provides a conservative 
estimate of improvement. 
Results 
Study patients. Of 194 patients creened, 100 met ambu- 
latory monitoring criteria and were randomized. Clinical and 
demographic features of randomized patients are shown in 
Table 1. Coronary artery disease was documented by angiog- 
raphy in 57 patients, positive radionuclide t st results in 28 and 
a previous myocardial infarction in 29. Some patients met 
more than one criterion. During baseline treadmill testing, 
angina was present in 28 of 51 patients in the amlodipine group 
and 22 of 49 in the atenolol group. Total exercise time 
averaged 399 _+ 145 s (mean _+ SD), time to onset of angina 
averaged 278 _+ 123 s, and time to onset of 0.1-mV ST segment 
depression averaged 226 _+ 128 s. Maximal ST segment 
depression averaged 0.253 + 0.09 mV. During baseline ambu- 
latory monitoring, the median number of ischemic episodes 
was 7 (range 2 to 38), and the median total duration of 
ischemia was 45.5 min (range 4 to 519). 
Eighty-two patients completed the study: 44 of 51 in the 
amlodipine group and 38 of 49 in the atenolol group. In the 
amlodipine group, one patient was withdrawn for administra- 
tive reasons and six because of side effects (two during placebo, 
one during active single-drug therapy and three during combi- 
nation therapy). In the atenolol group, three patients were 
withdrawn for administrative r asons and eight because of side 
effects (one during placebo, eight during active single-drug 
therapy and none during combination therapy). Of the 44 
patients in the amlodipine group, 40 received 10 mg daily, and 
4 received 5 mg daily. Of the 38 patients completing the 
protocol in the atenolol group, 35 received 100 mg daily, and 3 
received 50 mg daily. 
Suppression of isehemia. Exercise treadmill testing. During 
placebo, exercise times to 1.0- and 1.5-ram ST segment depres- 
sion averaged 258 and 331 s, respectively, with no significant 
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Table 2. Effect of Amlodipine and Atenolol on Heart Rate, Episode 
Frequency, Total Duration of Ischemia nd Cumulative ST Segment 
Time Integral During Ambulatory Monitoring 
Average Duration ST Segment Time 
Heart Rate Episode of Ischemia Integral 
(beats/rain) Frequent, (rain/48 h) (ram x rain/48 h) 
Amlodipine group 
Placebo 71 + 11 4.5 22.7 -31.6 
Single drug 76 + 11" 2.9 18.1 -25.8 
Combination 57 _+ 9t$ 1.5t$ 5.9.~ -7.8t~ 
Atenolol group 
Placebo 76 -+ 9 5.9 35.8 48.1 
Single drug 58 -+ 6t 2.5t 12.67 -16.4" 
Combination 60 + 5?$ 1.5t~ 8.4? -10.9t 
*p - 0.01, ?p = 0.001 versus placebo. ;p = 0.05 versus ingle drug. 
difference between the amlodipine and atenolol groups (Table 
2). The time to 0.1-mV ST segment depression was prolonged 
by 29% with amlodipine (p < 0.001), by 3% with atenolol (p = 
NS) and by 34% with the combination (p < 0.001 vs. placebo 
and atenolol; p < 0.05 vs. amlodipine). Exercise time to 
0.15-mV ST segment depression was prolonged by 14% with 
amlodipine (p < 0.001), by 8% with atenolol (p = NS) and by 
17% with the combination (p< 0.001 vs. placebo and atenolol; 
p = NS vs. amlodipine). 
Ambulatory monitoring. Atenolol produced a 57% suppres- 
sion in episode frequency during ambulatory monitoring (p < 
0.001). A 28% reduction with amlodipine did not reach 
statistical significance (p = 0.083). The combination of amlo- 
dipine and atenolol produced a 72% reduction in episode 
frequency, which was significantly greater than placebo and 
either single drug (p < 0.05 vs. both single drugs; p < 0.001 vs. 
placebo). Amlodipine caused a mild increase in average heart 
rate during ambulatory monitoring, whereas atenolol and the 
combination caused a substantial decrease. Figure 2 compares 
the drugs' effectiveness in suppressing ischemia during ambu- 
latory monitoring with that observed uring exercise treadmill 
testing. 
Effect on exercise treadmill testing times. Time to angina. 
Angina during treadmill testing was present in 28 of 44 patients 
completing the study in the amlodipine group and 19 of 38 in 
the atenolol group. Exercise time to angina averaged 279 _+ 
124 s, with no significant difference between the two groups. It 
was increased by 29% with amlodipine (p < 0.01), by 16% with 
atenolol (p < 0.05) and by 39% with the combination (p < 
0.005 vs. placebo, atenolol and amlodipine). 
Total exercise time. During placebo, total exercise time 
averaged 424 +_ 162 s, with no significant difference between 
the amlodipine and atenolol groups. It averaged 356 _+ 136 s in 
patients with angina during treadmill testing versus 515 _+ 149 s 
in those without angina (p < 0.0001). Amlodipine improved 
exercise time by 9% (p < 0.001 vs. placebo) overall, 16% in 
those with (p < 0.001) versus 3% in those without (p = NS) 
angina. Atenolol improved exercise time by 3% overall, 4% in 
those with and 2% in those without (all p = NS) angina. The 
combination improved exercise time by 13% (p < 0.01 vs. 
AECG ETT 
(Median episode frequency) (Time to isehemia onset) 
Amlodipine 
Atenolol 
Combination 
* p < 0.001 
I J 
100 80 60 40 20 0 10 20 30 40 50 
% change from placebo 
Figure 2. Relative fficacies ofamlodipine, atenolol and their combi- 
nation on time to ischemia during treadmill exercise time versus 
episode frequency during ambulatory monitoring. Atenolol caused a
greater reduction i ischemia during ambulatory monitoring, whereas 
amlodipine caused agreater delay in onset of ischemia during tread- 
mill exercise. The combination was more effective than either single 
drug in both settings. AECG = ambulatory electrocardiogram', ETI" = 
exercise treadmill test. 
placebo and atenolol; p < 0.05 vs. amlodipine), 19% in subjects 
with angina (p < 0.01 vs. placebo and atenolol; p < 0.05 vs. 
amlodipine) and 6% in those without angina (p < 0.05 vs. 
placebo; p = NS vs. either single drug). Therefore, amlodipine 
and combination therapy significantly improved treadmill ex- 
ercise time only in patients with angina during treadmill 
testing. 
To clarify this result, we compared ischemia suppression i
patients with and without angina. Amlodipine delayed isch- 
emia onset during exercise testing by 26% (p < 0.01) and 29% 
(p < 0.01) in patients with and without angina, respectively 
(p = NS). Combination therapy delayed ischemia onset by 
33% (p < 0.01) and 34% (p < 0.01), respectively, in patients 
with and without angina (p = NS), whereas atenolol did not 
significantly delay ischemia in either subgroup. During ambu- 
latory monitoring, atenolol reduced ischemia by 53% (p < 
0.01) in those with and by 63% (p < 0.01) in those without (p = 
NS) angina, whereas combination therapy suppressed ischemia 
by 69% (p < 0.01) and 79% (p < 0.01), respectively, in patients 
with and without angina (p = NS). The majority of ischemic 
episodes during ambulatory monitoring were silent regardless 
of therapy (95% during placebo, 93% during amlodipine, 97% 
during atenolol and 98% during combination therapy, p = 
NS). These data suggest that the drug treatments were equally 
effective in suppressing silent and symptomatic schemia but 
that only the suppression of symptomatic schemia improved 
exercise tolerance. 
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Table 3. Hemodynamic Variables at 0.l-mV ST Segment 
Depression During Ambulatory Monitoring and Exercise 
Treadmill Testing 
Ambulatory Treadmill Testing 
Monitoring 
Heart Rate Heart Rate Systolic BP Double 
(beats/rain) (beats/min) (ram Hg) Product 
Amlodipine group 
Placebo 92 116 161 18,798 
Single drug 96 120 158 19,325 
Combination 75'~ 1065§ 151*t 16,269t5 
Atenolol group 
Placebo 98 121 162 19,527 
Single drug 79* 1035 153' 15,730:~ 
Combination 79* 1065 1505 15,620"r5 
*p = 0.05, Sp - 0.001 versus placebo, tp = 0.05, §p - 0.001 versus single 
drug. 
Hemodynamic variables at onset of ischemia. During tread- 
mill testing, amlodipine produced no significant difference in 
the double product at 0.1-mV ST segment depression despite 
a 29% increase in the exercise time to this end point. Atenolol 
significantly reduced the heart rate, systolic pressure and 
double product at onset of ischemia, whereas atenolol and the 
combination caused a significant decrease (Table 3). Combi- 
nation therapy produced results similar to atenolol alone. 
During ambulatory monitoring, amlodipine caused a signifi- 
cant elevation in heart rate at onset of ischemia. 
Adverse vents. Fourteen patients withdrew because of ad- 
verse events (placebo [n = 3], amlodipine [n = 1], atenolol 
[n = 7], combination [n = 3] (Table 4). Although the rates of 
adverse ffects during atenolol and combination therapy were 
equivalent and approximately double those observed uring 
amlodipine and placebo therapy, the low frequency of side 
effects precluded statistical comparisons. 
Discuss ion  
The present study found the relative anti-ischemic efficacy 
of amlodipine and atenolol to differ during treadmill testing 
and ambulatory monitoring. During treadmill testing, amlodip- 
ine but not atenolol significantly delayed onset of ischemia. 
During ambulatory monitoring, atenolol caused a statistically 
significant reduction in the frequency of ischemia, whereas a 
smaller eduction with amlodipine was not significant. During 
both treadmill testing and ambulatory monitoring, the combi- 
nation was more effective than either drug given alone. These 
results support he idea that the pathophysiology of ischemia 
differs in these two settings and suggest hat the actions of 
amlodipine and atenolol are complementary. 
Mechanism of action of amlodipine. Dihydropyridine cal- 
cium channel blockers reduce coronary tone, decrease coro- 
nary vasoreactivity and lower cardiac demand by reducing 
afterload (25,26). Consistent with studies of other dihydropy- 
ridines (27-30), amlodipine delayed angina during treadmill 
testing and improved total exercise time in patients with 
angina. However, amlodipine increased treadmill testing time 
to onset of ischemia without altering the double product at this 
end point, suggesting that reduction of ischemia is mediated 
predominantly by a decrease in cardiac work load at a given 
level of exercise rather than by improved blood supply to 
ischemic areas. Similar findings have been reported in previous 
studies of other dihydropyridines (27,28,31). 
Mechanism of action of atenolol. Beta-blockers have been 
shown to improve survival (32,33) and are the most effective 
class of drugs for suppressing ischemia during ambulatory 
monitoring (9-13). Despite this, atenolol reduced both the 
double product at onset of ischemia during treadmill testing 
and heart rate at onset of ischemia during ambulatory moni- 
toring. These observations uggest hat beta-blockade may 
cause a reduction in absolute myocardial blood supply that 
partially offsets the beneficial effect of lowered cardiac de- 
mand. This possibility is consistent with the known coronary 
vasoconstrictor effects of beta-blockers (34,35). 
Differences between treadmill testing and ambulatory mon- 
itoring ischemia. The relative efficacies of amlodipine and 
atenolol differed for treadmill testing and ambulatory moni- 
toring. This suggests that there are important differences in the 
pathophysiology of ischemia in these two settings. Similar to 
earlier studies (36), we found that onset of ischemia during 
ambulatory monitoring occurred at lower heart rates than 
Table 4. Adverse Events 
Placebo Amlodipine Atenolol Combination 
(n = 96) (n = 50) (n = 48) (n = 85) 
No. of pts with any adverse event 42 (43.8%) 
No. of events with possible or 96 
unknown relation to drug 
Event rate/pt evaluated 1.0 
No. of events requiring 3 (3.1%) 
discontinuation of study drug 
Details of events requiring 
discontinuation of study drug 
19 (38%) 28 (58.3%) 47 (55.3%,) 
61) 100 172 
1.2 2.0 2.0 
1 (2%) 7 (14.6%) 3 (3.6%) 
MI, angina, Pressure at base of throat Headache, angina, dry mouth and Edema nd headache, 
ruptured AAA fatigue, dizziness and fatigue, bradycardia (n - 2) 
bronchospasm, nausea and 
dizziness, hypotension 
AAA = abdominal ortic aneurysm; MI - myocardial nfarction; pt(s) = patient(s). 
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during treadmill testing, which may be because this study used 
the Bruce protocol. Others (37) have shown that heart rate at 
onset of ischemia is lower with more gradual exercise proto- 
cols. 
More recent studies (4,38-41) have emphasized the impor- 
tance of increased cardiac demand in causing ambulatory 
monitoring ischemia. In agreement with this concept, we found 
that the majority of ischemic episodes were associated with an 
immediately preceding heart rate increase. Differences be- 
tween treadmill testing and ambulatory monitoring ischemia 
may relate to the dissimilarities in the provoking stimuli. 
Episodes of ambulatory monitoring ischemia usually occur 
during sedentary activity and can be provoked by mental stress 
(42,43), cold exposure (44) and tobacco smoke (45). Psycho- 
logic stressors, especially situations that trigger emotional 
distress, cause increases in heart rate and blood pressure and 
may trigger coronary vasoconstriction. Beta-blockers, possibly 
through their effects on the central nervous ystem, may be 
particularly effective at inhibiting these responses. A better 
understanding of the nature of response patterns during 
psychologic stress may therefore help to explain the advantage 
of beta-blockers during ambulatory monitoring. 
Potential biases. There are a number of factors affecting 
recruitment in studies such as this that may influence the 
results. First, the requirement for ischemia during ambulatory 
monitoring as well as treadmill exercise testing restricted the 
study patients to those with relatively severe ischemia. This is 
evidenced by a baseline maximal ST segment depression 
averaging >2.5 mm and mean time to onset of ischemia of only 
4 rain 13 s. Second, the fact that the patients' usual physician 
approved participation i  a placebo-controlled study restricted 
the study to those with relatively mild symptoms, as evidenced 
by the fact that -50% did not report angina during treadmill 
exercise. Finally, the exclusion of patients with recent unstable 
angina or myocardial infarction may influence the relative 
importance of supply and demand in provoking ischemia 
during ambulatory monitoring. Although the majority of epi- 
sodes in this study were associated with increased cardiac 
demand, other studies (46-48) have shown that ischemia in 
unstable coronary syndromes has little or no associated change 
in heart rate. These results apply to patients with relatively 
severe ischemia nd mild symptoms, and different results might 
be obtained in other patients. 
Clinical implications. Although amlodipine appeared to 
be more effective during treadmill testing, and atenolol ap- 
peared to be more effective during ambulatory monitoring, the 
combination was significantly better than either single drug in 
both testing situations. This suggests hat the real advantage of
these drugs may be their complementary modes of action. Our 
results agree with previous studies (11,16-20) in suggesting 
that the combination of a beta-blocker with a long-acting 
dihydropyridine such as amlodipine is an effective pharmaco- 
logic strategy for suppressing both silent and symptomatic 
ischemia. 
Conclusions. The present results underscore the need for 
further research into the utility of treating silent ischemia. 
Although pharmacologic therapy suppressed treadmill testing 
and ambulatory monitoring ischemia in patients with and 
without exercise-induced angina, exercise times improved only 
in those with overt angina. It is not known whether treating 
asymptomatic is hemia during treadmill testing or ambulatory 
monitoring improves prognosis, and a trial that will test this 
hypothesis in the planning stage (49). 
We acknowledge the secretarial ssistance of Kimberly McLaughlin in manu- 
script preparation and the assistance of Aida Dessain in data analysis. 
Appendix 
CASIS Centers and Investigators 
Universi~' of Ottawa Heart Institute, Ottawa, Ontario: Dr. Richard F. Davies, 
Dr. Habibullah Habibi, Dr. Kathy Foris. Department of Community Medicine and 
Epidemiolo~,, University of Ottawa, Ottawa, Ontario: Dr. Sankaranarayanan 
Raman, Ms. Margaret Herbert. Hopital de l'Enfant-Jesus, Quebec, Province of 
Quebec: Dr. Claude Nadeau. lmtitute de Recherches Cliniques de Montreal, 
Montreal, Province of Quebec: Dr. Denis C. Phaeneuf. Toronto General Hospital, 
Toronto, Ontario: Dr. Peter P. Liu. Royal Alexandria Hospital, Edmonton, Alberta: 
Dr. W. Peter Klinke. Foothills Hospital, Calgary, Alberta: Dr. J. Wayne Warnica. 
Western Cardiology Associates, Victoria, British Columbia: Dr. Jorge F. Bonet. 
Institute de Cardiologie de Montreal, Montreal, Province of Quebec: Dr. Andrew 
Pasternac. Centre Hospitalier Universitaire de Sherbmoke, Sherbrooke, Province of 
Quebec: Dr. Serge Lepage, Dr. Jean Rouleau. P~er Canada, Pointe Claire, 
Province of Quebec: Dr. Pierre Dessain, Ms. Jennifer Buttars. Department of
Psycholog% University of British Colombia, Vancouver, British Columbia: Dr. 
Wolfgang Linden. 
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